MDNA Logo

Medicenna Therapeutics Corp. (MDNA) Stock Forecast & Price Prediction

Live MDNA Stock Price & Analysis

Home โ€บ Stocks โ€บ Canada | NASDAQ | Healthcare | Biotechnology

$0.16

-0.87 (-84.76%)

12 Month Price Forecast For MDNA

$0.16
Current Price
$10.93M
Market Cap
0 Ratings
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to MDNA Price Forecasts

N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A

MDNA Price Momentum

0.0%
1 Week Change
-84.5%
1 Month Change
-77.8%
1 Year Change
-85.7%
Year-to-Date Change
-92.8%
From 52W High of $2.17
+3.8%
From 52W Low of $0.15

๐Ÿค” Considering Medicenna (MDNA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 14, 2025 12:36 PM UTC

MDNA Analyst Ratings & Price Targets

MDNA has shown a year-to-date change of -85.7% and a 1-year change of -77.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MDNA. Please refer to the price chart above for recent performance and trends.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MDNA Analyst Consensus

0
Buy
0
Hold
0
Sell

MDNA Price Target Range

Low
N/A
Average
N/A
High
N/A
Current: $0.16

Latest MDNA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MDNA.

Date Firm Analyst Rating Change Price Target
Dec 6, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $2.50
Aug 14, 2023 Oppenheimer Matthew Biegler Outperform Maintains $3.00
Aug 10, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $2.50
Jul 31, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $2.50
Jun 28, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $2.50
Feb 8, 2023 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $2.50
Nov 8, 2022 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $2.50
Aug 16, 2022 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $4.00
Jun 23, 2022 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $5.00
Jun 23, 2022 Oppenheimer Matthew Biegler Outperform Maintains $10.00
Jun 1, 2021 HC Wainwright & Co. Swayampakula Ramakanth Buy Maintains $7.00
Dec 18, 2020 Oppenheimer Outperform Initiates $0.00
Dec 17, 2020 Oppenheimer Outperform Initiates $0.00
Nov 25, 2020 HC Wainwright & Co. Buy Initiates $0.00
Sep 10, 2020 HC Wainwright & Co. Buy Initiates $0.00

Stocks Similar to Medicenna Therapeutics Corp.

The following stocks are similar to Medicenna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Medicenna Therapeutics Corp. (MDNA) Financial Data

Medicenna Therapeutics Corp. has a market capitalization of $10.93M with a P/E ratio of -1.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of -34.1%.

Valuation Metrics

Market Cap $10.93M
Enterprise Value $0
P/E Ratio -1.0x
PEG Ratio 0.0x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin N/A
Net Margin N/A
EPS Growth N/A

Financial Health

Cash/Price Ratio 0.0%
Current Ratio 7.5x
Debt/Equity 0.0x
ROE -34.1%
ROA -27.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp. (MDNA) Company Overview

About Medicenna Therapeutics Corp.

What They Do

Develops immunotherapies for cancer treatment.

Business Model

Medicenna Therapeutics Corp. focuses on the development and commercialization of innovative immunotherapy treatments, specifically Superkines and empowered Superkines. The company generates revenue through the development of its drug candidates, which are designed to enhance immune responses against cancer and autoimmune diseases, with multiple products advancing through various stages of clinical trials.

Additional Information

The company's lead product, MDNA55, targets recurrent glioblastoma, while MDNA11 and MDNA209 aim to activate immune cells and treat autoimmune conditions, respectively. Medicenna also offers its proprietary BiSKITs platform for creating customized Superkines, expanding its potential market opportunities. Headquartered in Toronto, Canada, the company is positioned within a growing sector focused on advanced cancer therapies.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

16

CEO

Dr. Fahar Merchant Ph.D.

Country

Canada

IPO Year

2015

Medicenna Therapeutics Corp. (MDNA) Latest News & Analysis

MDNA stock latest news image
Quick Summary

Medicenna Therapeutics will present findings from its Phase 2b trial of bizaxofusp at the Society for Neuro-Oncology Annual Meeting from November 15-19, 2023, in Vancouver.

Why It Matters

Medicenna's upcoming presentation at a key oncology meeting highlights progress in its IL-4R targeted therapy, potentially influencing investor confidence and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
MDNA stock latest news image
Quick Summary

Medicenna's MDNA11 shows promising results in the ABILITY-1 study, with significant tumor reductions in pancreatic and melanoma patients. The treatment is well tolerated with no severe side effects.

Why It Matters

Positive clinical results for MDNA11 in advanced solid tumors enhance Medicenna's growth potential, signaling strong therapeutic prospects and possibly increased market interest and investment.

Source: GlobeNewsWire
Market Sentiment: Neutral
MDNA stock latest news image
Quick Summary

Medicenna Therapeutics (NASDAQ: MDNA) stock is declining after receiving a delisting notice from Nasdaq's Listing Qualifications Department.

Why It Matters

Medicenna Therapeutics' delisting notice raises concerns about its financial stability and compliance, potentially leading to decreased investor confidence and stock value.

Source: InvestorPlace
Market Sentiment: Negative
MDNA stock latest news image
Quick Summary

The Company's listing on the Toronto Stock Exchange remains unaffected.

Why It Matters

Stable listings signal confidence and continuity, reducing volatility risk and maintaining investor trust in the company's market presence.

Source: GlobeNewsWire
Market Sentiment: Neutral
MDNA stock latest news image
Quick Summary

Medicenna Therapeutics Corp. will present posters at the SITC Annual Meeting in San Diego from November 1-5, 2023, focusing on its Superkines immunotherapy developments.

Why It Matters

Medicenna's participation at a prominent immunotherapy conference could attract investor interest, signal progress in their research, and potentially influence stock performance based on new data or partnerships.

Source: GlobeNewsWire
Market Sentiment: Neutral
MDNA stock latest news image
Quick Summary

New data from a Phase 1 trial will be presented at the SITC Annual Meeting on November 4, 2023, potentially impacting investor interest in related biotech firms.

Why It Matters

Upcoming trial results could impact stock prices of companies involved in cancer therapies, influencing investor sentiment and potential market opportunities.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About MDNA Stock

What is Medicenna Therapeutics Corp.'s (MDNA) stock forecast for 2025?

Analyst forecasts for Medicenna Therapeutics Corp. (MDNA) are not currently available. The stock is trading at $0.16.

Is MDNA stock a good investment in 2025?

Analyst ratings for MDNA are not currently available. The stock is currently trading at $0.16. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MDNA stock?

Price predictions from Wall Street analysts for MDNA are not currently available. The stock is trading at $0.16.

What is Medicenna Therapeutics Corp.'s business model?

Medicenna Therapeutics Corp. focuses on the development and commercialization of innovative immunotherapy treatments, specifically Superkines and empowered Superkines. The company generates revenue through the development of its drug candidates, which are designed to enhance immune responses against cancer and autoimmune diseases, with multiple products advancing through various stages of clinical trials.

What is the highest forecasted price for MDNA Medicenna Therapeutics Corp.?

Price targets from Wall Street analysts for MDNA are not currently available. The stock is trading at $0.16.

What is the lowest forecasted price for MDNA Medicenna Therapeutics Corp.?

Price targets from Wall Street analysts for MDNA are not currently available. The stock is trading at $0.16.

What is the overall MDNA consensus from analysts for Medicenna Therapeutics Corp.?

Analyst ratings for MDNA are not currently available. The stock is trading at $0.16.

How accurate are MDNA stock price projections?

Stock price projections, including those for Medicenna Therapeutics Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.